{"id":154765,"date":"2026-11-03T01:24:16","date_gmt":"2026-11-03T01:24:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/154765\/"},"modified":"2026-11-03T01:24:16","modified_gmt":"2026-11-03T01:24:16","slug":"novartis-calls-avidity-bump-normal-sticks-to-bolt-on-ma-strategy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/154765\/","title":{"rendered":"Novartis Calls Avidity \u2018Bump\u2019 Normal, Sticks To Bolt-On M&#038;A Strategy"},"content":{"rendered":"<p><a aria-label=\"Scrip home\" class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" height=\"70px\" src=\"https:\/\/insights.citeline.com\/pf\/resources\/images\/sectionsLogo\/scrip.svg?d=171\" alt=\"Scrip logo\"\/><\/a><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/business\" rel=\"nofollow noopener\" target=\"_blank\"><a class=\"c-link\" href=\"https:\/\/insights.citeline.com\/scrip\/business\/earnings\" rel=\"nofollow noopener\" target=\"_blank\"><\/p>\n<p class=\"c-paragraph b-subheadline-paragraph\">Novartis CEO Vas Narasimhan backs the company\u2019s current M&amp;A strategy, which is mainly focused on bolt-on deals under $2bn. <\/p>\n<p><img decoding=\"async\" data-chromatic=\"ignore\" alt=\"Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.\" class=\"c-image\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/11\/YJRWPP7TKBJYDIGJPXKQQ4B7BI.jpg\" width=\"700\" height=\"394\"\/> \u2022 Source: Archive <\/p>\n<p class=\"c-paragraph\">Novartis booked a $1.9bn partial impairment on del-desiran after the drug\u2019s Phase III failure, but CEO Vas Narasimhan said the hit to its $12bn Avidity Biosciences acquisition does not change a strategy built on bolt-on deals under $2bn.<\/p>\n<p>Key TakeawaysNovartis took a $1.9bn partial impairment on del-desiran after its Phase III failure, and a further pivotal study in myotonic dystrophy type 1 will delay any launch.<\/p>\n<p class=\"c-paragraph\">Speaking to reporters after third-quarter results, Narasimhan said the combined effect of the <a href=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\/neurological\/novartis-stock-sinks-10-as-del-desiran-flops-in-phase-iii-DNFVAIJUGBD3VFRPCI7SFDXUKQ\/\" target=\"_blank\" rel=\"nofollow sponsored noopener\" title=\"https:\/\/insights.citeline.com\/scrip\/therapeutic-category\/neurological\/novartis-stock-sinks-10-as-del-desiran-flops-in-phase-iii-DNFVAIJUGBD3VFRPCI7SFDXUKQ\/\">del-desiran<\/a> and&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis CEO Vas Narasimhan backs the company\u2019s current M&amp;A strategy, which is mainly focused on bolt-on deals under&hellip;\n","protected":false},"author":2,"featured_media":154766,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[13808,62199,72546,206,72544,72545],"class_list":["post-154765","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-avidity","tag-del-desiran","tag-narasimhans-outlook","tag-novartis","tag-novartis-q3-earnings","tag-rhapsido-urticaria-treatment"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117549902582079094","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/154765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=154765"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/154765\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/154766"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=154765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=154765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=154765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}